3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
13
Endometrial Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms
4
Neoplasms
3
Uterine Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Melanoma
1
Laryngeal Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Hyperglycemia
1
High Grade Serous Ovarian Cancer
1
Head and Neck Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Fallopian Tube Neoplasms
1
Interventions
Cyclophosphamide
3
isatuximab
2
Lenalidomide
2
Dexamethasone
2
pomalidomide
1
penpulimab
1
olaparib
1
niraparib
1
fludarabine
1
anlotinib
1
Sorafenib
1
Rituximab
1
Ranitidine
1
Oxaliplatin
1
Gemcitabine
1
Diphenhydramine
1
Chemoradiotherapy
1
Bortezomib
1
Bevacizumab
1
Bendamustine Hydrochloride
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms by Histologic Type
×
olaparib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled